Felvizumab Biosimilar - Research Grade

Human

RSV

>1mg/ml

IgG1 - kappa

CHO Cells

Motavizumab Biosimilar - Research Grade (ICH5169), Clesrovimab Biosimilar - Research Grade (ICH5441), Gontivimab Biosimilar - Research Grade (ICH5580), Nirsevimab Biosimilar - Research Grade (ICH5712), Suptavumab Biosimilar - Research Grade (ICH5887)

https://www.imgt.org/mAb-DB/

ICH3002

Blue ice

This product is a research-grade biosimilar of felvizumab, supplied as an unconjugated, non-therapeutic analog of the originator antibody for research use only. It is not a clinical drug. Felvizumab is a humanized IgG1 kappa monoclonal antibody directed against respiratory syncytial virus (RSV), derived by grafting the complementarity-determining regions of a murine anti-RSV antibody (RSV19/RSHZ19) onto human heavy- and light-chain frameworks. The biosimilar reproduces the originator's binding specificity and is built around the RSV target rather than around a proprietary hybridoma clone, making it a defined reference reagent for characterising RSV neutralisation and comparing anti-F-protein antibodies. It is produced as a bulk-scale, low-endotoxin preparation (research grade, less than 1 EU/mg) suitable for demanding in-vitro and functional workflows where lot consistency and format matter. Typical applications include serving as a benchmark neutralising antibody, a positive control in binding and fusion-inhibition assays, and a comparator in assay development. Provided for research use only; each user should validate performance for their specific application. Respiratory syncytial virus (RSV) is an enveloped negative-sense RNA pneumovirus and a leading cause of lower respiratory tract infection in infants, older adults, and immunocompromised patients. Entry and cell-to-cell spread depend on the fusion (F) glycoprotein, which drives merger of the viral envelope with the host cell membrane by transitioning from a metastable prefusion conformation to a stable postfusion state. Because the F protein is highly conserved across RSV subgroups, it is the dominant target for neutralising antibodies. Felvizumab recognises an epitope on the F protein (reported around residues 417-432), a region overlapping antigenic sites bound by other clinically studied anti-F antibodies. Antibodies engaging F can block fusion and thereby prevent productive infection, which is the mechanistic basis for using such antibodies as neutralising reagents and controls in RSV research.

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Felvizumab biosimilar available in bulk or gram quantities?

A: Yes — the Felvizumab biosimilar is manufactured in scalable milligram to gram quantities to support high-throughput and heavy-usage laboratories.

Q: Is this research-grade Felvizumab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Felvizumab biosimilar bind?

A: It is an unconjugated, non-therapeutic analog of Felvizumab that recognises RSV.